{"prompt": "['MK-7902', 'PAGE 22', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 6 Censoring Rules for Time-to-Deterioration', 'Scenario', 'Outcome', 'Deterioration documented', 'Event observed at time of assessment (first deterioration)', 'Ongoing, death or discontinued from study', 'Right censored at time of last assessment', 'without deterioration', 'No baseline assessments', 'Right censored at treatment start date', '3.6.3.5.', 'Overall Improvement and Overall Improvement/Stability', 'Overall improvement rate will be analyzed, which is defined as the proportion of participants', 'who have achieved an improvement as defined in Section 3.4.3 PRO Endpoints. The point', 'estimate of overall proportions of participants who have achieved an improvement, stability, and', 'deterioration will be provided by treatment group together with 95% CI using exact binomial', \"method by Clopper and Pearson (1934). Stratified Miettinen and Nurminen's method will be\", 'used for comparison of the overall improvement rate between the treatment groups. The', 'difference in overall improvement rate and its 95% CI, along with nominal two-sided p-values,', \"from the stratified Miettinen and Nurminen's method with strata weighting by sample size will\", 'be provided. The stratification factors used for randomization (see Section 6.3.2 in protocol) will', 'be applied to the analysis.', 'The same method will be used to analyze overall improvement/stability rate, which is defined', 'as', 'the proportion of participants who have achieved improvement/stability as defined in Section', '3.4.3 PRO Endpoints.', '3.6.3.6.', 'Analysis Strategy for Key PRO Enppoints', 'A summary of the analysis strategy for the key PRO endpoints is provided in Table 7.', 'C', 'Confidential']['MK-7902', 'PAGE 23', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 7 Analysis Strategy for Key PRO Endpoints', 'Endpoint/Variable', 'Statistical Method', 'Analysis', 'Missing Data Approach', 'Population', 'Mean change from baseline in', 'cLDA model', 'FAS', 'Model-based.=cLDA', '- EORTC QLQ-C30', 'Global health status/QoL', 'Physical functioning', 'dyspnea', '- EORTC QLQ-LC13', 'Cough', 'Chest pain', 'TTD in', 'Stratified log-rank test and', 'FAS', 'Censored according to', '- EORTC QLQ-C30', 'HR estimation using', 'rules in Table 6.', 'Global health status/QoL', 'stratified Cox model with', 'Physical functioning', \"Efron's tie handling method\", 'dyspnea', '- EORTC QLQ-LC13', 'Cough', 'Chest pain', 'Overall improvement and', 'Stratified Miettinen and', 'FAS', 'Participants with missing', 'overall improvement/stability', 'Nurminen method', 'data are considered not', 'in', 'achieving', '- EORTC QLQ-C30', 'improvement/stability.', 'Global health status/QoL', 'Physical functioning', 'dyspnea', '- EORTC QLQ-LC13', 'Cough', 'Chest pain', 'Abbreviations: cLDA = constrained longitudinal data analysis, FAS = full analysis set, QoL = quality of life.', '3.6.4.', 'Demographic and Baseline Characteristics', 'The comparability of the treatment groups for each relevant demographic and baseline', 'characteristic will be assessed by the use of tables and/or graphs. No statistical hypothesis tests', 'will be performed on these characteristics. The number and percentage of participants screened', 'and randomized and the primary reason for screening failure and discontinuation will be', 'displayed. Demographic variables, baseline characteristics, primary and secondary diagnoses,', 'and prior and concomitant therapies will be summarized by treatment, either by descriptive', 'statistics or categorical tables.', '3.7. Interim Analyses', 'Blinding to treatment assignment will be maintained at all investigational sites. The results of', 'interim analyses will not be shared with the investigators before the completion of the study.', 'Participant-level unblinding will be restricted to an external unblinded statistician and scientific', 'Confidential']\n\n###\n\n", "completion": "END"}